ACP
BNTC icon

Acuta Capital Partners’s Benitec Biopharma BNTC Stock Holding History

Acuta Capital Partners’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-29,800
Closed -$274K – 40
2024
Q3 		$274K Buy
+29,800
New +$267K 0.22% 38

Other funds holding BNTC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acuta Capital Partners's BNTC Position: Q4 2024 in Review

Acuta Capital Partners sold out of Benitec Biopharma (BNTC) in Q4 2024, closing a stake of 29,800 shares — an estimated $274K sold.

Acuta Capital Partners first reported a position in BNTC in Q3 2024 and held it in 1 quarter. The position peaked at $274K in Q3 2024. 30 funds tracked by Wall St. Rank hold BNTC as of Q4 2024.

  • Acuta Capital Partners reported no remaining Benitec Biopharma position as of Q4 2024 after selling out during the quarter.
  • Acuta Capital Partners sold 29,800 Benitec Biopharma shares in Q4 2024, an estimated $274K.
  • Acuta Capital Partners first reported a position in Benitec Biopharma in Q3 2024 and held it in 1 quarter.
  • Acuta Capital Partners's Benitec Biopharma position peaked at $274K in Q3 2024.
  • 30 funds tracked by Wall St. Rank held Benitec Biopharma as of Q4 2024.

Based on Acuta Capital Partners's 13F filing for Q4 2024, filed 14 Feb 2025.